CJC-1295 (No DAC) research

The CJC-1295 evidence base cited here is 6 sources — 2 clinical, 3 preclinical, 1 review. Its strongest evidence is human — 2 clinical studies, most recently 2006 ("Teichman et al. — CJC-1295 Pharmacokinetics in Humans"). Regulatory status: Not FDA-approved.

• CJC-1295 without DAC — also called Modified GRF 1-29 (Mod GRF 1-29) — is a short-acting synthetic analog of growth-hormone-releasing hormone (GHRH).
• Its defining feature is a very SHORT half-life (~30 minutes), which produces brief, pulsatile GH release that mimics the body's natural secretion pattern — the opposite design goal of the DAC version.
• That pulsatility is the whole point: it raises GH and IGF-1 without the continuous, non-physiological elevation (and desensitization risk) seen with long-acting analogs.

CJC-1295 without DAC (Mod GRF 1-29) is a stabilized fragment of GHRH that stimulates the pituitary to release growth hormone in natural-style pulses. Where the DAC version is engineered for long, continuous action, the non-DAC variant is deliberately short-acting — it spikes GH and clears quickly, preserving the pulsatile rhythm that normal GH physiology depends on.

It is investigational, not FDA-approved, and everything below is research context rather than medical guidance.

It is a modified GHRH(1-29) peptide — 30 amino acids, ~3,368 Da — with amino-acid substitutions that improve enzymatic stability over native GHRH (about 4× greater receptor affinity and resistance to DPP-4 breakdown, per comparative work), while still clearing rapidly.

Crucially, it does NOT carry the Drug Affinity Complex (DAC) that binds albumin. Without DAC, the half-life stays short (~30 minutes), which is what keeps GH release pulsatile rather than continuous.

Half-life note: the intended, study-supported half-life is ~30 minutes (Teichman et al., 2006). Any source citing a multi-day half-life for the NON-DAC version has almost certainly confused it with the DAC variant — the short half-life is the entire reason the non-DAC form exists.

• Teichman et al. (2006) — characterized the GHRH-analog PK, the basis for the ~30-minute non-DAC half-life.
• CJC-1295 vs native GHRH (in vitro + human): ~4× greater receptor affinity and improved enzymatic resistance vs native GHRH.

Not FDA-approved for any use; sold as a research chemical for laboratory use only, not intended for human consumption. GH-axis peptides may also fall under sport anti-doping prohibitions — tested athletes should verify with their governing body.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.